WA
BMRN icon

Waddell & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waddell & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Sell
5,470
-3,900
-42% -$214K 0.02% 391
2026
Q1 		$529K Buy
9,370
+4,490
+92% +$262K 0.03% 221
2025
Q4 		$290K Sell
4,880
-296
-6% -$16.1K 0.02% 286
2025
Q3 		$280K Sell
5,176
-615
-11% -$35.2K 0.02% 226
2025
Q2 		$318K Buy
+5,791
New +$341K 0.03% 157

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Waddell & Associates's BMRN Position: Q2 2026 in Review

Waddell & Associates reduced its BioMarin Pharmaceuticals (BMRN) stake by 42% in Q2 2026, selling an estimated $214K and leaving 5,470 shares worth $313K. The position accounts for 0.02% of the portfolio, ranked #391.

Waddell & Associates first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $529K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Waddell & Associates held 5,470 shares of BioMarin Pharmaceuticals worth $313K as of Q2 2026.
  • Waddell & Associates sold 3,900 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $214K.
  • BioMarin Pharmaceuticals made up 0.02% of Waddell & Associates's portfolio in Q2 2026, its #391 holding.
  • Waddell & Associates first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Waddell & Associates's BioMarin Pharmaceuticals position peaked at $529K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.